Skip to main content
. 2016 Mar 18;130(9):667–681. doi: 10.1042/CS20150622

Figure 6. The ROS/AMPK/p38 pathway is involved in IL-1β-induced NF-κB activation and FGF-2 expression.

Figure 6

ATDC5 cells were incubated with IL-1β for the indicated times, and p65 phosphorylation was examined by Western blotting (A; n=8). ATDC5 cells were pre-treated with TPCK or PDTC for 30 min, and then stimulated with IL-1β for 24 h. FGF-2 expression was examined by Western blotting (B; n=8) and ELISA (C; n=6). ATDC5 cells were pre-treated with DPI, NAC, Ara A, Compound C or SB203580 for 30 min, and then stimulated with IL-1β for 30 min, after which NF-κB (p65) phosphorylation was examined by Western blotting (D; n=8). ATDC5 cells were incubated with IL-1β at different dosages for 24 h, or pre-treated with DPI, NAC, Ara A, Compound C, SB203580, TPCK or PDTC for 30 min before stimulation with IL-1β for 24 h. NF-κB luciferase activity was measured (E and F; n≥8). Quantification results are expressed as means±S.D. *P<0.05 compared with the Con group; #P<0.05 compared with the IL-1β-treated group in (F). Molecular masses are indicated in kDa. β-Actin was used as a loading control.